title: Augmentation of M-type (KCNQ) potassium channels as a novel strategy to reduce stroke-induced brain injury.
abstract: Cerebral ischemic stroke is a worldwide cause of mortality/morbidity and thus an important focus of research to decrease the severity of brain injury. Therapeutic options for acute stroke are still limited. In neurons throughout the brain, "M-type" K(+) currents, underlain by KCNQ subunits 2-5, play dominant roles in control over excitability, and are thus implicated in myriad neurological and psychiatric disorders. Although KCNQ channel openers, such as retigabine, have emerged as anti-epilepsy drugs, their effects on ischemic injury remain unknown. Here, we investigated the protective effects of M-channel openers on stroke-induced brain injury in mouse photothrombotic and middle cerebral artery occlusion (MCAo) models. Both photothrombosis and MCAo led to rapid, predictable, and consistently sized necrotic brain lesions, inflammatory responses, and behavioral deficits. Administration of three distinct M-channel openers at 0-6 h after ischemic injury significantly decreased brain infarct size and inflammation, and prevented neurological dysfunction, although they were more effective when administered 0-3 h poststroke. Thus, we show beneficial effects against stroke-induced brain injury and neuronal death through pharmacological regulation of ion channels that control neuronal excitability.
authors: Departments of Physiology and.
authors: Sonya M
authors: SM
authors: Bierbower
authors: Departments of Physiology and.
authors: Frank S
authors: FS
authors: Choveau
authors: Cellular and Structural Biology, University of Texas Health Science Center, San Antonio, Texas 78229.
authors: James D
authors: JD
authors: Lechleiter
authors: Departments of Physiology and shapirom@uthscsa.edu.
authors: Mark S
authors: MS
authors: Shapiro
mesh_terms: D000818:Animals; D000873:Anthracenes / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D002219:Carbamates / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D020244:Infarction, Middle Cerebral Artery / Q000188:drug therapy*; D051656:KCNQ Potassium Channels / Q000819:agonists / Q000037:antagonists & inhibitors*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D010655:Phenylenediamines / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D026902:Potassium Channel Blockers / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: C112297:10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone; D000873:Anthracenes; D002219:Carbamates; D051656:KCNQ Potassium Channels; D010655:Phenylenediamines; D026902:Potassium Channel Blockers; C101866:ezogabine
keywords: ischemia; motor deficits; pathological disease; potassium channel; stroke
references: Nat Neurosci. 2005 Jan;8(1):51-60
references: 15608631
references: PLoS One. 2012;7(12):e53266
references: 23285272
references: J Psychopharmacol. 2005 May;19(3):221-7
references: 15888506
references: NeuroRx. 2004 Jan;1(1):17-25
references: 15717004
references: NeuroRx. 2004 Jan;1(1):36-45
references: 15717006
references: Nat Rev Neurosci. 2005 Nov;6(11):850-62
references: 16261179
references: Neurosci Lett. 2006 Jan 30;393(2-3):108-12
references: 16233958
references: Neuropharmacology. 2006 Aug;51(2):283-94
references: 16697426
references: Methods Mol Biol. 2006;337:27-38
references: 16929936
references: J Neurosci. 2006 Nov 22;26(47):12325-38
references: 17122058
references: Curr Opin Pharmacol. 2008 Feb;8(1):65-74
references: 18061539
references: Br J Pharmacol. 2008 Mar;153 Suppl 1:S396-405
references: 18157168
references: Acta Pharmacol Sin. 2013 Jan;34(1):24-32
references: 23123646
references: J Cardiovasc Pharmacol. 2013 Jan;61(1):51-62
references: 23107868
references: Physiol Res. 2013;62(1):85-94
references: 23173682
references: J Cereb Blood Flow Metab. 2013 Apr;33(4):600-11
references: 23321785
references: J Neurosci. 2013 Apr 3;33(14):6041-6
references: 23554485
references: J Transl Med. 2013;11:34
references: 23394517
references: Stroke. 1986 Nov-Dec;17(6):1304-8
references: 2433817
references: Stroke. 1989 Jan;20(1):84-91
references: 2643202
references: Neurochem Res. 1991 Sep;16(9):951-63
references: 1686067
references: J Physiol. 1995 Jun 1;485 ( Pt 2):319-35
references: 7666361
references: Acta Neuropathol. 1996 Sep;92(3):255-63
references: 8870827
references: J Biol Chem. 1997 Aug 1;272(31):19569-74
references: 9235962
references: Nat Genet. 1998 Jan;18(1):25-9
references: 9425895
references: J Pharmacol Exp Ther. 2008 May;325(2):475-83
references: 18272810
references: Lancet. 2008 May 10;371(9624):1612-23
references: 18468545
references: J Physiol. 2008 Jul 15;586(14):3405-23
references: 18483067
references: J Neurosci Res. 2008 Oct;86(13):2973-83
references: 18512761
references: Neurobiol Dis. 2009 Jan;33(1):1-11
references: 18930826
references: Stroke. 2009 Feb;40(2):604-9
references: 19023097
references: PLoS One. 2010;5(12):e14401
references: 21203502
references: Mol Pharmacol. 2000 Aug;58(2):253-62
references: 10908292
references: Mol Pharmacol. 2000 Sep;58(3):591-600
references: 10953053
references: Arzneimittelforschung. 2000 Dec;50(12):1063-70
references: 11190770
references: Nat Med. 2001 Jan;7(1):59-64
references: 11135617
references: Neurosci Lett. 2001 Feb 16;299(1-2):37-40
references: 11166932
references: Nat Med. 2001 Apr;7(4):471-7
references: 11283675
references: J Neurosci Methods. 2002 Apr 15;115(2):169-79
references: 11992668
references: Neuropharmacology. 2002 Jun;42(7):950-7
references: 12069905
references: Ann Neurol. 2003 Jun;53(6):693-702
references: 12783414
references: J Clin Invest. 2003 Jun;111(12):1843-51
references: 12813020
references: Nat Med. 2003 Oct;9(10):1313-7
references: 12960961
references: Free Radic Biol Med. 2003 Dec 15;35(12):1619-31
references: 14680685
references: Stroke. 1977 Jan-Feb;8(1):51-7
references: 13521
references: Brain Res Bull. 2011 Aug 10;86(1-2):42-52
references: 21669260
references: Science. 1998 Jan 16;279(5349):403-6
references: 9430594
references: J Pharmacol Exp Ther. 1998 May;285(2):724-30
references: 9580619
references: Ann Med. 2011 Aug;43(5):331-40
references: 21244217
references: Ann Neurol. 1985 May;17(5):497-504
references: 4004172
references: Epilepsia. 2012 Mar;53(3):412-24
references: 22220513
references: Nat Neurosci. 2012 Apr;15(4):565-73
references: 22388960
references: Circulation. 2013 Jan 1;127(1):21-3
references: 23239838
references: J Physiol. 2005 Jan 1;562(Pt 1):81-8
references: 15528238